美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

PagerDuty, Inc.

14.62

0.0000

盘后：14.620.00000.00%19:37 EDT

成交量：80.26万

成交额：1,178.11万

市值：13.48亿

市盈率：-36.30

高：14.85

开：14.76

低：14.60

收：14.62

数据加载中...

总览公司新闻公告

三生制药(01530)与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)订立许可协议

广东优力普物联科技取得PD供电电路专利，电路原理简单成本低

【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。

创新药生存法则生变：PD-1价格腰斩倒逼国际化转型，BD授权成第二增长引擎

21世纪经济报道

辉瑞(PFE)PD-L1 ADC在国内启动Ⅰ期临床

辉瑞(PFE.US)PD-L1 ADC在国内首次启动临床

阿斯利康PD-L1单抗一项III期研究成功

从PD-1跟随到多款ADC领先，乐普生物-B（02157）迎价值重估？

【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。

百济神州一季度亏损大幅收窄国内BTK抑制剂销售加速、PD-1销售减速

每日经济新闻

基石药业(02616)重磅发布CS2009(PD-1/VEGF/CTLA-4)最新临床前研究结果

港股异动 | 三生制药(01530)再涨超9% 抗VEGF/PD-1双特异性抗体707被纳入突破性治疗品种

康方生物依沃西获批用于PD-L1阳性肺癌治疗

【康方生物(09926.HK)：依达方®(依沃西，PD-1/VEGF)第二个适应症上市申请获得NMPA批准用于一线治疗PD-L1阳性NSCLC】康方生物(09926.HK)发布公告，由公司自主研发的全球首创双特异性抗体依达方®(依沃西，PD-1/VEGF)单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA)，已获得中国国家药品监督管理局(NMPA)批准上市。这是依沃西获批上市的第二个适应症，让中国患者“率先用上全球最优治疗方案”成为现实。

康方生物(09926.HK)：依达方®(依沃西，PD-1/VEGF)第二个适应症上市申请获得NMPA批准，用于一线治疗PD-L1阳性NSCLC

【康方生物(09926.HK)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准两项适应症用于治疗晚期鼻咽癌】康方生物(09926.HK)发布公告，安尼可®(派安普利，PD-1)已获得美国食品药品监督管理局(FDA)批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。

康方生物(09926)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准两项适应症用于治疗晚期鼻咽癌

港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO

港股异动 | 基石药业-B(02616)最高涨超7% 三抗CS2009（PD-1/VEGF/CTLA-4）即将在AACR更新更多数据

荣获七项ASCO口头报告：信达生物IBI363（PD-1/IL-2α-bias）领衔多款管线亮相美国临床肿瘤学会2025年大会

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/PD/news?page=5"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":14.62,"timestamp":1753128000000,"preClose":14.62,"halted":0,"volume":802599,"hourTrading":{"tag":"盘后","latestPrice":14.62,"preClose":14.62,"latestTime":"19:37 EDT","volume":45621,"amount":666993.05,"timestamp":1753141061962},"delay":0,"floatShares":82117609,"shares":92173975,"eps":-0.402741,"marketStatus":"未开盘","change":0,"latestTime":"07-21 16:00:00 EDT","open":14.76,"high":14.85,"low":14.6,"amount":11781082.652934,"amplitude":0.0171,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.402741,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753171200000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":14.62,"preHourTrading":{"tag":"盘前","latestPrice":14.79,"preClose":14.62,"latestTime":"09:15 EDT","volume":59,"amount":867.91006,"timestamp":1753103719016},"postHourTrading":{"tag":"盘后","latestPrice":14.62,"preClose":14.62,"latestTime":"19:37 EDT","volume":45621,"amount":666993.05,"timestamp":1753141061962},"volumeRatio":0.57893,"impliedVol":0.5338,"impliedVolPercentile":0.564},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PD\",,,,,undefined,":{"symbol":"PD","floatShares":82117609,"roa":"-3.27%","roe":"-19.13%","lyrEps":-0.591956,"volumeRatio":0.57893,"shares":92173975,"dividePrice":0,"high":14.85,"amplitude":0.0171,"preClose":14.62,"low":14.6,"week52Low":13.695,"pbRate":"9.25","psRate":"2.83","week52High":22.02,"institutionHeld":0,"latestPrice":14.62,"eps":-0.402741,"divideRate":0,"volume":802599,"delay":0,"ttmEps":-0.402741,"open":14.76,"prevYearClose":18.26,"prevWeekClose":14.62,"prevMonthClose":15.28,"prevQuarterClose":15.28,"fiveDayClose":14.96,"twentyDayClose":13.92,"sixtyDayClose":15.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PD\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2536115655","title":"三生制药(01530)与辉瑞就PD-1/VEGF双特异性抗体(SSGJ-707)订立许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2536115655","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536115655?lang=zh_cn&edition=fundamental","pubTime":"2025-05-20 07:11","pubTimestamp":1747696265,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药 发布公告，于2025年5月19日，公司、沈阳三生制药有限责任公司及辉瑞公司(辉瑞)已订立独家许可协议。根据许可协议，公司及沈阳三生将向辉瑞授予独家许可，以在全球开发、生产、商业化及以其他方式开发其突破性PD-1/VEGF双特异性抗体。辉瑞应负责承担许可产品在许可地区内的所有未来试验的开发及监管事务的所有费用。该许可产品为集团基于其专有CLF2平台自主研发的靶向PD-1/VEGF的双特异性抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1295063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0225771236.USD","LU1057294990.SGD","LU0306807586.USD","LU0456855351.SGD","LU0225284248.USD","PD","BK4550","SG9999013999.USD","BK4568","IE0002270589.USD","LU0058720904.USD","LU0289739699.SGD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","SG9999001176.USD","SG9999002232.USD","BK4007","LU0321505439.SGD","LU0985481810.HKD","LU0234572021.USD","LU1066051498.USD","LU0868494617.USD","BK4585","IE00B19Z3B42.SGD","SG9999003800.SGD","IE00B19Z3581.USD","LU0122379950.USD","SG9999002224.SGD","BK4581","LU0306806265.USD","LU1169589451.USD","SG9999011175.SGD","BK1583","BK1593","LU1894683348.USD","IE00BLSP4239.USD","LU1894683264.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1023059063.AUD","LU0170899867.USD","LU1883839398.USD","BK4599","SG9999001176.SGD","BK4588","BK4592","01530","BK4533","BK4534"],"gpt_icon":1},{"id":"2536387372","title":"广东优力普物联科技取得PD供电电路专利，电路原理简单成本低","url":"https://stock-news.laohu8.com/highlight/detail?id=2536387372","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536387372?lang=zh_cn&edition=fundamental","pubTime":"2025-05-17 12:02","pubTimestamp":1747454547,"startTime":"0","endTime":"0","summary":"天眼查资料显示，广东优力普物联科技有限公司，成立于2014年，位于东莞市，是一家以从事计算机、通信和其他电子设备制造业为主的企业。通过天眼查大数据分析，广东优力普物联科技有限公司共对外投资了4家企业，参与招投标项目9次，财产线索方面有商标信息56条，专利信息94条，此外企业还拥有行政许可6个。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/17120250471652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PD","LU1169590202.USD","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2535358846","title":"【研报掘金丨国证国际：恒瑞医药为领先创新型制药企业 予港股IPO专用评级“6.1”】国证国际研报指出，恒瑞医药(1276.HK)是一家根植中国、全球领先的创新型制药企业。2024年公司营收279.85亿元（+22.6%）、归母净利润63.37亿元（+47.3%），毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。其中PD-L1&TGF-β、HER2ADC等重磅品种即将持续放量，叠加海外授权合作，形成“国内放量+海外授权”双轮驱动。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535358846","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535358846?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 14:19","pubTimestamp":1747376389,"startTime":"0","endTime":"0","summary":"2024年公司营收279.85亿元、归母净利润63.37亿元，毛利率提升1.6pct至86.2%。核心增长引擎为创新药收入，创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。公司此次IPO发行价为41.45-44.05港元，较A股股价有24-28%的折价，对应24年PE为40x-42.4x。公司研发实力雄厚，定价相较A股有较大折扣，且近期港股市场打新热情较为高涨，综合考虑给予IPO专用评级“6.1”。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/16141950441814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PD","399300","01477","06978","600276","YANG","HSCEI","159982","01276","HSTECH","159992"],"gpt_icon":0},{"id":"2535502832","title":"创新药生存法则生变：PD-1价格腰斩倒逼国际化转型，BD授权成第二增长引擎","url":"https://stock-news.laohu8.com/highlight/detail?id=2535502832","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535502832?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 19:08","pubTimestamp":1747220900,"startTime":"0","endTime":"0","summary":"当前，我国医药行业正在逐渐从“高成长”阶段进入“高质量成长”阶段，创新药也进入成果兑现阶段。Wind数据显示，今年一季度医药生物行业有60家公司营收超10亿元，其中，2家公司营收超百亿元，7家公司营收在50亿元至百亿元之间。一季度，医药生物行业有281家公司归母净利润为正，其中84家超亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505143404570068.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505143404570068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2535271637","title":"辉瑞(PFE)PD-L1 ADC在国内启动Ⅰ期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2535271637","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535271637?lang=zh_cn&edition=fundamental","pubTime":"2025-05-13 16:27","pubTimestamp":1747124827,"startTime":"0","endTime":"0","summary":"金吾财讯 | 5月12日，药物临床试验登记与信息公示平台显示，辉瑞(PFE)在国内启动了一项PF-08046054针对实体瘤患者的Ⅰ期临床。PF-08046054(SGN-PDL1V)是辉瑞收购Seagen获得的一款靶向PD-L1的ADC。这项Ⅰ期临床旨在评估PF-08046054作为单药治疗晚期实体恶性肿瘤受试者。Insight数据库显示，全球目前共有2款靶向PD-L1的ADC进入临床阶段。除了辉瑞的PF-08046054，另外一款为宜联生物/复宏汉霖的HLX43，目前正在开展Ⅱ期临床阶段。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MDE2NGUxYWJlMGQ4OGQwMTU5ZTY5YzEzNTY0MzU1Mzgx.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"288443","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4452.SGD","LU1894683348.USD","IE00B19Z3B42.SGD","SG9999013999.USD","LU0321505439.SGD","BK4581","SG9999002232.USD","PFE","BK4231","BK4007","IE00BLSP4239.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0306807586.USD","BK4592","LU1066053197.SGD","LU1066051498.USD","LU0122379950.USD","PD","BK4023","IE00BBT3K403.USD","LU0234572021.USD","LU1169589451.USD","LU1057294990.SGD","SG9999001176.SGD","LU0225284248.USD","LU0868494617.USD","BK4534","BK4588","LU0225771236.USD","LU0170899867.USD","LU1894683264.USD","SGXZ57979304.SGD","IE0002270589.USD","BK4585","LU0058720904.USD","SG9999001176.USD","ADC","LU0321505868.SGD","LU0985481810.HKD","SG9999002224.SGD","SG9999003800.SGD","IE00B19Z3581.USD","LU1883839398.USD","BK4599","SG9999011175.SGD","BK4550","BK4568","LU0456855351.SGD","BK4080"],"gpt_icon":0},{"id":"2535713135","title":"辉瑞(PFE.US)PD-L1 ADC在国内首次启动临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2535713135","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535713135?lang=zh_cn&edition=fundamental","pubTime":"2025-05-13 16:02","pubTimestamp":1747123376,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月12日，药物临床试验登记与信息公示平台显示，辉瑞在国内启动了一项PF-08046054针对实体瘤患者的Ⅰ期临床。研究的主要终点指标是安全性，次要终点指标是有效性。Insight数据库显示，全球目前共有2款靶向PD-L1的ADC进入临床阶段。除了辉瑞的PF-08046054，另外一款为宜联生物/复宏汉霖的HLX43，目前正在开展Ⅱ期临床阶段。此外，还有三款靶向PD-L1的双靶点ADC进入临床，分别来自信达、映恩、康宁杰瑞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292471.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE000M9KFDE8.USD","SG9999011175.SGD","PFE","LU1883839398.USD","BK4599","SG9999003800.SGD","BK4585","BK4588","SG9999001176.SGD","SG9999002224.SGD","LU1894683348.USD","LU0225284248.USD","LU0868494617.USD","BK4231","SG9999001176.USD","IE00BLSP4452.SGD","LU0321505868.SGD","LU1169589451.USD","BK4080","LU1894683264.USD","BK4533","LU1057294990.SGD","LU1169590202.USD","LU0170899867.USD","LU0225771236.USD","LU1066051498.USD","BK4592","BK4550","LU0234572021.USD","LU0058720904.USD","PD","IE0002270589.USD","LU1066053197.SGD","SGXZ57979304.SGD","BK4007","IE00B19Z3B42.SGD","LU0321505439.SGD","SG9999002232.USD","BK4568","LU0306806265.USD","LU0306807586.USD","LU0456855351.SGD","BK4534","ADC","LU0122379950.USD","IE00BBT3K403.USD","BK4023","SG9999013999.USD","LU1023059063.AUD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2534120879","title":"阿斯利康PD-L1单抗一项III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2534120879","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534120879?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 15:39","pubTimestamp":1746776382,"startTime":"0","endTime":"0","summary":"5月9日，阿斯利康宣布Imfinzi联合标准治疗治疗高危非肌层浸润性膀胱癌患者的III期POTOMAC研究取得了积极的高水平结果。结果显示，治疗一年后，与BCG组相比，度伐利尤单抗+BCG组患者的无疾病生存期显著延长且具有临床意义。膀胱癌是世界上第九大最常见的癌症，全球每年有超过61.4万例新诊断病例。目前NMIBC的SOC是TURBT术后+BCG。高达80%的患者在5年内出现疾病复发，高危患者的疾病进展率可高达45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509155609a6d8c3f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","III","AZN","BK4585","BK4588","LU2456880835.USD","LU2462157665.USD","LU1169589451.USD","LU0109394709.USD","LU1169590202.USD","PD","LU2236285917.USD","BK4134","BK4007","LU1829250122.USD","LU2417539215.USD","LU0889565916.HKD","BK4568","BK4023"],"gpt_icon":0},{"id":"2534457851","title":"从PD-1跟随到多款ADC领先，乐普生物-B（02157）迎价值重估？","url":"https://stock-news.laohu8.com/highlight/detail?id=2534457851","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534457851?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 12:15","pubTimestamp":1746764144,"startTime":"0","endTime":"0","summary":"作为肿瘤治疗领域的新秀，乐普生物-B以PD-1为资本市场所熟知，也因上市初期仅PD-1进展最快，因此自上市以来，乐普生物股价表现并不如意。据wind显示，乐普生物当前股价较2022年上市初期仍处于腰斩状态。得益于PD-1的商业化，2024年乐普生物实现营业收入3.68 亿元人民币，同比增长63.21%。目前乐普生物的在研管线中核心药物为MRG003。乐普生物的免疫疗法中，普特利单抗已上市，加上公司有多款在研的ADC药物，因此联合疗法也成了乐普生物积极布局的方向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4080","BK1161","LU1169590202.USD","02157","BK4023","ADC","BK4231","LU1169589451.USD","PD"],"gpt_icon":0},{"id":"2534119680","title":"【加科思-B(01167.HK)：SHP2抑制剂SITNEPROTAFIB联用研究数据发表于学术期刊】加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534119680","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534119680?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 06:46","pubTimestamp":1746744399,"startTime":"0","endTime":"0","summary":"加科思-B(01167.HK)发布公告，公司自主研发的SHP2抑制剂sitneprotafib (JAB-3312)相关研究见刊Clinical Cancer Research(《临床肿瘤研究》)。文章公布了SHP2抑制剂与PD-1抗体以及靶向RTK/RAS/MAPK通路的联合疗法中的临床前体内外数据和对联合疗法有回应的代表性患者病例。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09064650243257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4023","BK1161","PD","BK1574","01167","LU1169590202.USD","LU1169589451.USD"],"gpt_icon":0},{"id":"2533932462","title":"百济神州一季度亏损大幅收窄 国内BTK抑制剂销售加速、PD-1销售减速","url":"https://stock-news.laohu8.com/highlight/detail?id=2533932462","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533932462?lang=zh_cn&edition=fundamental","pubTime":"2025-05-07 22:41","pubTimestamp":1746628873,"startTime":"0","endTime":"0","summary":"作为国内创新药龙头企业，百济神州目前有3款主要自研产品，分别为BTK抑制剂泽布替尼、PD-1单抗替雷利珠单抗和PARP抑制剂帕米帕利。对于一季度的产品收入增长，公司归因于百悦泽、百泽安及安进授权产品的销售增长。具体来说，今年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%。而在竞争更为激烈的国内PD-1单抗市场中，百泽安实现销售额12.45亿元，同比增长19.3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050722420597521340&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1169589451.USD","688235","BK4023","LU1169590202.USD","ONC","PD","BK4139","06160"],"gpt_icon":0},{"id":"2533595272","title":"基石药业(02616)重磅发布CS2009(PD-1/VEGF/CTLA-4)最新临床前研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2533595272","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533595272?lang=zh_cn&edition=fundamental","pubTime":"2025-05-06 08:26","pubTimestamp":1746491219,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月6日，基石药业，一家专注于抗肿瘤药物研发的创新驱动型生物医药企业，宣布公司在2025年美国癌症研究协会年会上，以壁报形式公布研发管线2.0重磅产品CS2009的临床前研究结果。在肿瘤免疫治疗领域，PD-1、VEGFA和CTLA-4是经临床验证的有效靶点，三者间的协同机制可实现多维度的抗肿瘤效应。CS2009是一款同时靶向PD-1/VEGFA/CTLA-4三特异性抗体，在实体瘤治疗领域具有广阔的临床应用前景。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1289351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","PD","BK4023","LU1169589451.USD","LU1169590202.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"2532724863","title":"港股异动 | 三生制药(01530)再涨超9% 抗VEGF/PD-1双特异性抗体707被纳入突破性治疗品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2532724863","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532724863?lang=zh_cn&edition=fundamental","pubTime":"2025-05-02 11:48","pubTimestamp":1746157731,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药再涨超9%，截至发稿，涨9.53%，报13.1港元，成交额1.22亿港元。消息面上，三生制药发布公告，该公司自主研发的抗VEGF/PD-1双特异性抗体于2025年4月17日获国家药品监督管理局纳入突破性治疗品种，适应症为一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌。关注三生制药等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PD","BK1583","01530","BK1161","LU1169589451.USD","LU1169590202.USD","BK1593","BK4023"],"gpt_icon":0},{"id":"2530549955","title":"康方生物依沃西获批用于PD-L1阳性肺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2530549955","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530549955?lang=zh_cn&edition=fundamental","pubTime":"2025-04-28 09:32","pubTimestamp":1745803955,"startTime":"0","endTime":"0","summary":"4月27日，康方生物（09926）发布公告，宣布其自主研发的双特异性抗体依达方?（依沃西，PD-1/VEGF）获得中国国家药品监督管理局（NMPA）批准，用于一线治疗PD-L1阳性非小细胞肺癌（NSCLC）。这是依沃西获得的第二个适应症，标志着中国患者能够率先使用全球最优治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504283390722024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348784397.USD","09926","LU2488822045.USD","BK4023","BK1574","LU1169589451.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0348783233.USD","LU1169590202.USD","LU1720050803.USD","BK1161","IE00BPRC5H50.USD","PD","LU0417516571.SGD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2530343711","title":"【康方生物(09926.HK)：依达方®(依沃西，PD-1/VEGF)第二个适应症上市申请获得NMPA批准 用于一线治疗PD-L1阳性NSCLC】康方生物(09926.HK)发布公告，由公司自主研发的全球首创双特异性抗体依达方®(依沃西，PD-1/VEGF)单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA)，已获得中国国家药品监督管理局(NMPA)批准上市。这是依沃西获批上市的第二个适应症，让中国患者“率先用上全球最优治疗方案”成为现实。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530343711","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530343711?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 20:01","pubTimestamp":1745755264,"startTime":"0","endTime":"0","summary":"康方生物(09926.HK)发布公告，由公司自主研发的全球首创双特异性抗体依达方®(依沃西，PD-1/VEGF)单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗的新药上市申请(sNDA)，已获得中国国家药品监督管理局(NMPA)批准上市。这是依沃西获批上市的第二个适应症，让中国患者“率先用上全球最优治疗方案”成为现实。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/27200149930796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BPRC5H50.USD","LU1794554557.SGD","ALK","LU0348784397.USD","BK1161","09926","BK4585","BK4023","PD","LU1169590202.USD","IE00B5MMRT66.SGD","LU1720050803.USD","LU1169589451.USD","LU0417516571.SGD","BK1574","LU2488822045.USD","IE00B543WZ88.USD","BK4008","LU0348783233.USD","BK4500","BK4588"],"gpt_icon":0},{"id":"2530379034","title":"康方生物(09926.HK)：依达方®(依沃西，PD-1/VEGF)第二个适应症上市申请获得NMPA批准，用于一线治疗PD-L1阳性NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2530379034","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530379034?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 19:58","pubTimestamp":1745755137,"startTime":"0","endTime":"0","summary":"格隆汇4月27日丨康方生物宣布，由公司自主研发的全球首创双特异性抗体依达方单药用于PD-L1阳性的表皮生长因子受体基因突变阴性和间变性淋巴瘤激酶阴性的局部晚期或转移性非小细胞肺癌的一线治疗的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第二个适应症，让中国患者‘‘率先用上全球最优治疗方案’’成为现实。依沃西是全球首个在头对头帕博利珠单抗的III期临床研究中获得显著阳性结果的药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27195849930778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1169589451.USD","LU0417516571.SGD","LU2488822045.USD","PD","LU1794554557.SGD","BK1574","BK4023","IE00B543WZ88.USD","LU0348783233.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0348784397.USD","BK1161","LU1169590202.USD","IE00B5MMRT66.SGD","09926"],"gpt_icon":1},{"id":"2530916455","title":"【康方生物(09926.HK)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准 两项适应症用于治疗晚期鼻咽癌】康方生物(09926.HK)发布公告，安尼可®(派安普利，PD-1)已获得美国食品药品监督管理局(FDA)批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。","url":"https://stock-news.laohu8.com/highlight/detail?id=2530916455","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530916455?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 08:18","pubTimestamp":1745540328,"startTime":"0","endTime":"0","summary":"康方生物(09926.HK)发布公告，安尼可®(派安普利，PD-1)已获得美国食品药品监督管理局(FDA)批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/25081849860793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0417516571.SGD","IE00BPRC5H50.USD","BK4023","LU1720050803.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD","LU1169590202.USD","159839","LU1169589451.USD","LU2488822045.USD","LU1794554557.SGD","PD","09926","BK1574","BK1161","LU0348784397.USD"],"gpt_icon":0},{"id":"2530191575","title":"康方生物(09926)安尼可®（派安普利，PD -1）获美国食品药品监督管理局批准 两项适应症用于治疗晚期鼻咽癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2530191575","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530191575?lang=zh_cn&edition=fundamental","pubTime":"2025-04-25 08:13","pubTimestamp":1745539980,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，安尼可已获得美国食品药品监督管理局批准上市，用于治疗复发或转移性鼻咽癌的一线治疗和以铂类为基础的至少一线化疗治疗失败后治疗的2项适应症。派安普利由公司自主研发并由正大天晴康方负责后续开发和商业化，也是公司第一个获得美国FDA批准上市的自主研发创新生物药。派安普利本次在美国获批上市，为全球的晚期鼻咽癌患者提供了免疫治疗新选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","PD","LU1169590202.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1161","BK4023","BK1574","LU0417516571.SGD","IE00BPRC5H50.USD","LU0348784397.USD","LU1794554557.SGD","LU1169589451.USD","LU0348783233.USD","09926"],"gpt_icon":0},{"id":"2529640246","title":"港股异动 | 信达生物(01801)涨超5% IBI363（PD-1/IL-2α-bias）等多款管线将亮相2025 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2529640246","media":"智通财经","labels":["conferences","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529640246?lang=zh_cn&edition=fundamental","pubTime":"2025-04-24 14:37","pubTimestamp":1745476662,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，信达生物涨超5%，截至发稿，涨5.05%，报54.05港元，成交额15.91亿港元。消息面上，4月24日，信达生物宣布将在美国临床肿瘤学会年会上展示肿瘤创新管线的一系列临床数据。其中，IBI363在黑色素瘤、肠癌、非小细胞肺癌的临床研究，以及 IBI343在胰腺癌研究方面均有口头报告。本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283860.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1589","LU2328871848.SGD","01801","LU2488822045.USD","BK4023","LU1169589451.USD","LU1169590202.USD","PD","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2529617317","title":"港股异动 | 基石药业-B(02616)最高涨超7% 三抗CS2009（PD-1/VEGF/CTLA-4）即将在AACR更新更多数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2529617317","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529617317?lang=zh_cn&edition=fundamental","pubTime":"2025-04-24 11:35","pubTimestamp":1745465743,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，基石药业-B早盘最高涨超7%，截至发稿，涨2.41%，报2.97港元，成交额1672.07万港元。基石药业5款自主研发创新药物的最新临床前研究成果将同时亮相这一国际顶级学术舞台，包括三抗CS2009、双抗CS2011及出自公司自有抗体偶联药物平台的三款创新ADC分子CS5006、CS5007与CS5005。其中90%用于与集团“管线2.0”中的资产，尤其是CS5001，以及CS2009有关的进一步研发；余下净额于适当时用于其他一般公司用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1283807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","PD","02616","BK1161","BK1574","LU1169590202.USD","BK4023"],"gpt_icon":0},{"id":"2529693739","title":"荣获七项ASCO口头报告：信达生物IBI363（PD-1/IL-2α-bias）领衔多款管线亮相美国临床肿瘤学会2025年大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529693739","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529693739?lang=zh_cn&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。信达生物制药集团高级副总裁周辉博士表示：\"很高兴在本次ASCO大会上，IBI363开发的第一批三大适应症黑色素瘤、肠癌、非小细胞肺癌的临床研究均被接收为口头报告，代表了下一代PD-1双抗肿瘤免疫疗法引起了全球的广泛关注。同时IBI343胰腺癌研究继去年12月ESMO Asia口头报告之后，再次以口头报告登上ASCO舞台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4671176_ZH71176_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169589451.USD","LU2328871848.SGD","BK4139","IVBIY","BK1583","BK1589","PD","01801","LU1169590202.USD","LU2488822045.USD","BK4023","BK1161","LU1969619763.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":163,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-29","symbol":"PD","fiscalQuarterEnding":"2025/04","expectedEps":-0.06,"name":null,"time":"盘后","type":"earning","dateTimestamp":1748491200000,"reportTimeType":"post","actualEps":0},{"market":"US","date":"2025-03-13","symbol":"PD","fiscalQuarterEnding":"2025/01","expectedEps":-0.12,"name":null,"time":"盘后","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-11-26","symbol":"PD","fiscalQuarterEnding":"2024/10","expectedEps":-0.11,"name":null,"time":"盘后","type":"earning","dateTimestamp":1732597200000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2024-09-03","symbol":"PD","fiscalQuarterEnding":"2024/07","expectedEps":-0.12,"name":null,"time":"盘后","type":"earning","dateTimestamp":1725336000000,"reportTimeType":"post","actualEps":-0.06},{"market":"US","date":"2024-05-30","symbol":"PD","fiscalQuarterEnding":"2024/04","expectedEps":-0.11,"name":null,"time":"盘后","type":"earning","dateTimestamp":1717041600000,"reportTimeType":"post","actualEps":-0.11}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.0909,"buy":0.3636,"hold":0.4545,"sell":0.0909,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.4545,"analysts":11,"updateTime":1738468800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PD","date":"2025-07-18","current":-36.593825,"percent":0.290804,"low":-81.051795,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"high":-13.794086,"avg":-30.245097,"sd":13.265016,"marketCap":1350348733},"quantilePoints":[{"date":"2020-07-24","current":-42.807044,"twenty":-72.640646,"median":-42.989625,"eighty":-37.118318,"marketCap":2128965516},{"date":"2020-07-31","current":-48.235072,"twenty":-72.530247,"median":-43.175427,"eighty":-37.208604,"marketCap":2398923066},{"date":"2020-08-07","current":-47.238087,"twenty":-72.318638,"median":-43.360924,"eighty":-37.407321,"marketCap":2349339026},{"date":"2020-08-14","current":-46.177802,"twenty":-72.098738,"median":-43.468321,"eighty":-37.467623,"marketCap":2296606793},{"date":"2020-08-21","current":-45.95625,"twenty":-71.69039,"median":-43.550826,"eighty":-37.518859,"marketCap":2285588118},{"date":"2020-08-28","current":-48.583225,"twenty":-71.41486,"median":-43.699242,"eighty":-37.630539,"marketCap":2416238127},{"date":"2020-09-04","current":-38.528058,"twenty":-71.368789,"median":-43.748751,"eighty":-37.658486,"marketCap":1997756875},{"date":"2020-09-11","current":-36.766338,"twenty":-71.24954,"median":-43.637964,"eighty":-37.464273,"marketCap":1906408152},{"date":"2020-09-18","current":-38.03784,"twenty":-70.931543,"median":-43.525964,"eighty":-37.424178,"marketCap":1972338100},{"date":"2020-09-25","current":-40.596165,"twenty":-70.750862,"median":-43.369188,"eighty":-37.464273,"marketCap":2104992334},{"date":"2020-10-02","current":-42.378825,"twenty":-69.760733,"median":-43.304333,"eighty":-37.506887,"marketCap":2197426830},{"date":"2020-10-09","current":-45.308378,"twenty":-68.893466,"median":-43.360924,"eighty":-37.540906,"marketCap":2349330024},{"date":"2020-10-16","current":-46.719472,"twenty":-68.681421,"median":-43.459295,"eighty":-37.566006,"marketCap":2422498055},{"date":"2020-10-23","current":-44.664183,"twenty":-67.026675,"median":-43.550718,"eighty":-37.624584,"marketCap":2315927228},{"date":"2020-10-30","current":-41.565912,"twenty":-65.321463,"median":-43.550772,"eighty":-37.657731,"marketCap":2155275682},{"date":"2020-11-06","current":-46.121291,"twenty":-64.742086,"median":-43.550826,"eighty":-37.676934,"marketCap":2391481172},{"date":"2020-11-13","current":-46.35136,"twenty":-63.787431,"median":-43.643849,"eighty":-37.728931,"marketCap":2403410742},{"date":"2020-11-20","current":-47.79313,"twenty":-62.855819,"median":-43.781756,"eighty":-37.757248,"marketCap":2478169382},{"date":"2020-11-27","current":-52.440537,"twenty":-62.329113,"median":-43.973974,"eighty":-37.811067,"marketCap":2719146700},{"date":"2020-12-04","current":-58.503982,"twenty":-61.897872,"median":-44.116471,"eighty":-37.910083,"marketCap":3346135266},{"date":"2020-12-11","current":-61.956348,"twenty":-61.897872,"median":-44.23472,"eighty":-37.979009,"marketCap":3543593297},{"date":"2020-12-18","current":-64.76408,"twenty":-63.261641,"median":-44.342085,"eighty":-38.134161,"marketCap":3704181571},{"date":"2020-12-24","current":-65.981719,"twenty":-64.468982,"median":-44.366057,"eighty":-38.286785,"marketCap":3773824445},{"date":"2020-12-31","current":-59.735947,"twenty":-64.377301,"median":-44.622066,"eighty":-38.319351,"marketCap":3416597468},{"date":"2021-01-08","current":-63.775644,"twenty":-64.248374,"median":-44.664183,"eighty":-38.342002,"marketCap":3647647944},{"date":"2021-01-15","current":-65.265461,"twenty":-64.491902,"median":-44.85652,"eighty":-38.342002,"marketCap":3732858049},{"date":"2021-01-22","current":-70.007091,"twenty":-64.924465,"median":-44.940871,"eighty":-38.368803,"marketCap":4004055593},{"date":"2021-01-29","current":-69.806539,"twenty":-66.010369,"median":-45.124322,"eighty":-38.447577,"marketCap":3992585002},{"date":"2021-02-05","current":-78.774094,"twenty":-67.606194,"median":-45.279297,"eighty":-38.515566,"marketCap":4505484287},{"date":"2021-02-12","current":-81.051795,"twenty":-68.875403,"median":-45.308378,"eighty":-38.533013,"marketCap":4635757427},{"date":"2021-02-19","current":-74.533844,"twenty":-69.256452,"median":-45.492434,"eighty":-38.599807,"marketCap":4262963219},{"date":"2021-02-26","current":-64.090797,"twenty":-69.256452,"median":-45.616009,"eighty":-38.656949,"marketCap":3665673158},{"date":"2021-03-05","current":-53.862628,"twenty":-69.159583,"median":-45.671397,"eighty":-38.66724,"marketCap":3080673016},{"date":"2021-03-12","current":-60.509506,"twenty":-69.072496,"median":-45.726784,"eighty":-38.673459,"marketCap":3460841176},{"date":"2021-03-19","current":-49.639711,"twenty":-68.918379,"median":-45.797998,"eighty":-38.687063,"marketCap":3420324980},{"date":"2021-03-26","current":-46.372989,"twenty":-68.782324,"median":-45.852876,"eighty":-38.706425,"marketCap":3195238028},{"date":"2021-04-01","current":-49.627656,"twenty":-68.703922,"median":-45.852876,"eighty":-38.74149,"marketCap":3419494401},{"date":"2021-04-09","current":-50.688437,"twenty":-68.634603,"median":-45.95625,"eighty":-38.792193,"marketCap":3492585367},{"date":"2021-04-16","current":-50.965686,"twenty":-68.620415,"median":-46.098464,"eighty":-38.810779,"marketCap":3511688688},{"date":"2021-04-23","current":-50.965686,"twenty":-68.551655,"median":-46.177802,"eighty":-38.849388,"marketCap":3511688688},{"date":"2021-04-30","current":-51.182664,"twenty":-68.073194,"median":-46.296231,"eighty":-38.932876,"marketCap":3526639113},{"date":"2021-05-07","current":-45.52431,"twenty":-67.425697,"median":-46.35136,"eighty":-39.005886,"marketCap":3136761501},{"date":"2021-05-14","current":-42.286432,"twenty":-67.150653,"median":-46.187891,"eighty":-39.046881,"marketCap":2913662055},{"date":"2021-05-21","current":-44.081211,"twenty":-66.824039,"median":-46.121291,"eighty":-39.054259,"marketCap":3037327665},{"date":"2021-05-28","current":-49.295769,"twenty":-66.574781,"median":-46.172553,"eighty":-39.081958,"marketCap":3396626399},{"date":"2021-06-04","current":-36.968776,"twenty":-66.216652,"median":-46.172553,"eighty":-39.072116,"marketCap":2957576028},{"date":"2021-06-11","current":-42.279901,"twenty":-66.096321,"median":-46.075636,"eighty":-39.072116,"marketCap":3382476656},{"date":"2021-06-18","current":-45.709132,"twenty":-65.976077,"median":-45.923735,"eighty":-39.125091,"marketCap":3656821944},{"date":"2021-06-25","current":-47.162372,"twenty":-65.815901,"median":-46.067026,"eighty":-39.183405,"marketCap":3773084124},{"date":"2021-07-02","current":-44.130431,"twenty":-65.216755,"median":-46.011638,"eighty":-39.205083,"marketCap":3530522741},{"date":"2021-07-09","current":-45.834591,"twenty":-65.021933,"median":-45.883552,"eighty":-39.229781,"marketCap":3666858967},{"date":"2021-07-16","current":-40.199362,"twenty":-64.900098,"median":-45.829869,"eighty":-39.313533,"marketCap":3216029363},{"date":"2021-07-23","current":-43.325398,"twenty":-64.76408,"median":-45.766347,"eighty":-39.330284,"marketCap":3466118512},{"date":"2021-07-30","current":-42.436726,"twenty":-64.636745,"median":-45.712576,"eighty":-39.369202,"marketCap":3395022935},{"date":"2021-08-06","current":-44.33953,"twenty":-64.491902,"median":-45.685037,"eighty":-39.631794,"marketCap":3547251112},{"date":"2021-08-13","current":-42.269446,"twenty":-64.377301,"median":-45.655572,"eighty":-39.648544,"marketCap":3381640238},{"date":"2021-08-20","current":-40.387552,"twenty":-64.32,"median":-45.516041,"eighty":-39.732297,"marketCap":3231084897},{"date":"2021-08-27","current":-43.743597,"twenty":-64.248374,"median":-45.492434,"eighty":-39.784241,"marketCap":3499575255},{"date":"2021-09-03","current":-42.390054,"twenty":-64.090797,"median":-45.440934,"eighty":-39.784241,"marketCap":4025995391},{"date":"2021-09-10","current":-39.410762,"twenty":-63.838675,"median":-45.357157,"eighty":-39.773852,"marketCap":3743037083},{"date":"2021-09-17","current":-42.488469,"twenty":-63.43184,"median":-45.291593,"eighty":-39.773852,"marketCap":4035342362},{"date":"2021-09-24","current":-41.531159,"twenty":-63.322968,"median":-45.131991,"eighty":-39.806871,"marketCap":3944421825},{"date":"2021-10-01","current":-37.845067,"twenty":-63.294318,"median":-44.969953,"eighty":-39.673042,"marketCap":3594335269},{"date":"2021-10-08","current":-35.304169,"twenty":-63.234694,"median":-44.895964,"eighty":-39.361418,"marketCap":3353013468},{"date":"2021-10-15","current":-36.968279,"twenty":-62.977151,"median":-44.757709,"eighty":-39.195032,"marketCap":3511062253},{"date":"2021-10-22","current":-37.567716,"twenty":-62.673,"median":-44.689179,"eighty":-39.048237,"marketCap":3567993805},{"date":"2021-10-29","current":-37.352992,"twenty":-62.144822,"median":-44.662724,"eighty":-38.884343,"marketCap":3547600413},{"date":"2021-11-05","current":-38.927633,"twenty":-61.970673,"median":-44.622066,"eighty":-38.780249,"marketCap":3697151952},{"date":"2021-11-12","current":-37.684024,"twenty":-61.914834,"median":-44.517265,"eighty":-38.690435,"marketCap":3579040225},{"date":"2021-11-19","current":-34.892615,"twenty":-61.891288,"median":-44.350719,"eighty":-38.663132,"marketCap":3313926135},{"date":"2021-11-26","current":-33.094304,"twenty":-61.87812,"median":-44.340807,"eighty":-38.647574,"marketCap":3143131480},{"date":"2021-12-03","current":-27.717262,"twenty":-61.851785,"median":-44.310434,"eighty":-38.490518,"marketCap":2632446965},{"date":"2021-12-10","current":-29.437491,"twenty":-61.634212,"median":-44.193031,"eighty":-38.342002,"marketCap":2964590848},{"date":"2021-12-17","current":-29.446029,"twenty":-61.446371,"median":-44.130431,"eighty":-38.122419,"marketCap":2965450648},{"date":"2021-12-23","current":-30.863263,"twenty":-61.141525,"median":-44.120926,"eighty":-37.910083,"marketCap":3108177469},{"date":"2021-12-31","current":-29.668005,"twenty":-60.679678,"median":-44.096614,"eighty":-37.767931,"marketCap":2987805451},{"date":"2022-01-07","current":-27.243339,"twenty":-60.561077,"median":-44.020576,"eighty":-37.685906,"marketCap":2743622214},{"date":"2022-01-14","current":-26.466422,"twenty":-60.402519,"median":-43.931787,"eighty":-37.609143,"marketCap":2665380403},{"date":"2022-01-21","current":-25.715117,"twenty":-60.229637,"median":-43.82863,"eighty":-37.535067,"marketCap":2589717991},{"date":"2022-01-28","current":-27.448241,"twenty":-60.179262,"median":-43.748751,"eighty":-37.457573,"marketCap":2764257417},{"date":"2022-02-04","current":-27.106738,"twenty":-60.125395,"median":-43.643849,"eighty":-37.310047,"marketCap":2729865412},{"date":"2022-02-11","current":-28.728874,"twenty":-59.884929,"median":-43.550718,"eighty":-37.143446,"marketCap":2893227437},{"date":"2022-02-18","current":-27.106738,"twenty":-59.724487,"median":-43.492185,"eighty":-36.968378,"marketCap":2729865412},{"date":"2022-02-25","current":-28.071482,"twenty":-59.678646,"median":-43.437917,"eighty":-36.905651,"marketCap":2827022827},{"date":"2022-03-04","current":-25.322389,"twenty":-59.583656,"median":-43.360924,"eighty":-36.834452,"marketCap":2550167185},{"date":"2022-03-11","current":-22.70136,"twenty":-59.306192,"median":-43.319423,"eighty":-36.766338,"marketCap":2286208545},{"date":"2022-03-18","current":-28.291592,"twenty":-59.172166,"median":-43.295217,"eighty":-36.444632,"marketCap":3040073042},{"date":"2022-03-25","current":-28.785804,"twenty":-59.048339,"median":-43.241759,"eighty":-36.064649,"marketCap":3093178556},{"date":"2022-04-01","current":-27.724464,"twenty":-59.048339,"median":-43.1764,"eighty":-35.678665,"marketCap":2979132288},{"date":"2022-04-08","current":-25.415442,"twenty":-58.958192,"median":-43.086807,"eighty":-35.293402,"marketCap":2731016361},{"date":"2022-04-14","current":-26.428171,"twenty":-58.866018,"median":-43.039133,"eighty":-34.945236,"marketCap":2839839136},{"date":"2022-04-22","current":-23.843687,"twenty":-58.778063,"median":-42.940117,"eighty":-34.48789,"marketCap":2562123414},{"date":"2022-04-29","current":-23.14693,"twenty":-58.704534,"median":-42.888728,"eighty":-33.407653,"marketCap":2487253345},{"date":"2022-05-06","current":-21.039181,"twenty":-58.614907,"median":-42.82356,"eighty":-33.196501,"marketCap":2260765197},{"date":"2022-05-13","current":-21.537198,"twenty":-58.533862,"median":-42.744231,"eighty":-33.138326,"marketCap":2314279623},{"date":"2022-05-20","current":-19.528801,"twenty":-58.506847,"median":-42.67719,"eighty":-32.784627,"marketCap":2098467346},{"date":"2022-05-27","current":-21.055509,"twenty":-58.47232,"median":-42.506172,"eighty":-32.56425,"marketCap":2262519768},{"date":"2022-06-03","current":-19.41561,"twenty":-58.365647,"median":-42.492303,"eighty":-32.253988,"marketCap":2285547362},{"date":"2022-06-10","current":-18.661968,"twenty":-58.119439,"median":-42.449993,"eighty":-31.627913,"marketCap":2196830881},{"date":"2022-06-17","current":-17.871017,"twenty":-57.794408,"median":-42.412967,"eighty":-30.853018,"marketCap":2103722495},{"date":"2022-06-24","current":-21.251213,"twenty":-57.545961,"median":-42.37641,"eighty":-30.527663,"marketCap":2501629088},{"date":"2022-07-01","current":-18.975364,"twenty":-57.27835,"median":-42.328632,"eighty":-30.205871,"marketCap":2233722883},{"date":"2022-07-08","current":-20.758734,"twenty":-57.119373,"median":-42.300639,"eighty":-29.937792,"marketCap":2443655942},{"date":"2022-07-15","current":-19.512613,"twenty":-57.022546,"median":-42.274674,"eighty":-29.686169,"marketCap":2296966315},{"date":"2022-07-22","current":-19.751391,"twenty":-56.538634,"median":-42.258991,"eighty":-29.576542,"marketCap":2325074507},{"date":"2022-07-29","current":-19.348454,"twenty":-55.37095,"median":-42.1379,"eighty":-29.489533,"marketCap":2277641933},{"date":"2022-08-05","current":-21.340755,"twenty":-54.581356,"median":-41.999461,"eighty":-29.249821,"marketCap":2512169660},{"date":"2022-08-12","current":-21.370602,"twenty":-54.282209,"median":-41.907002,"eighty":-28.899625,"marketCap":2515683184},{"date":"2022-08-19","current":-19.214141,"twenty":-54.164004,"median":-41.742363,"eighty":-28.761236,"marketCap":2261831075},{"date":"2022-08-26","current":-19.318607,"twenty":-54.013801,"median":-41.687142,"eighty":-28.490216,"marketCap":2274128409},{"date":"2022-09-02","current":-16.562766,"twenty":-53.825684,"median":-41.612639,"eighty":-28.401837,"marketCap":2096100841},{"date":"2022-09-09","current":-17.753369,"twenty":-53.67791,"median":-41.5952,"eighty":-28.368118,"marketCap":2246777593},{"date":"2022-09-16","current":-16.597991,"twenty":-53.584381,"median":-41.569297,"eighty":-28.257217,"marketCap":2100558733},{"date":"2022-09-23","current":-15.858267,"twenty":-53.533149,"median":-41.530643,"eighty":-28.105632,"marketCap":2006943000},{"date":"2022-09-30","current":-16.252786,"twenty":-53.345477,"median":-41.466004,"eighty":-27.873415,"marketCap":2056871391},{"date":"2022-10-07","current":-16.182337,"twenty":-53.110426,"median":-41.390601,"eighty":-27.717262,"marketCap":2047955607},{"date":"2022-10-14","current":-14.646529,"twenty":-52.79331,"median":-41.34773,"eighty":-27.636067,"marketCap":1853591514},{"date":"2022-10-21","current":-16.485271,"twenty":-52.578578,"median":-41.307589,"eighty":-27.328715,"marketCap":2086293479},{"date":"2022-10-28","current":-17.922449,"twenty":-52.484531,"median":-41.281723,"eighty":-27.012825,"marketCap":2268175475},{"date":"2022-11-04","current":-14.604259,"twenty":-52.445692,"median":-41.223096,"eighty":-26.683037,"marketCap":1848242043},{"date":"2022-11-11","current":-17.35885,"twenty":-52.440537,"median":-41.165581,"eighty":-26.46868,"marketCap":2196849202},{"date":"2022-11-18","current":-15.442613,"twenty":-51.97825,"median":-41.046215,"eighty":-26.415612,"marketCap":1954339874},{"date":"2022-11-25","current":-15.379208,"twenty":-51.971496,"median":-40.952393,"eighty":-26.24103,"marketCap":1946315669},{"date":"2022-12-02","current":-16.042428,"twenty":-51.941247,"median":-40.886211,"eighty":-26.002015,"marketCap":2129728606},{"date":"2022-12-09","current":-16.110204,"twenty":-51.872986,"median":-40.837833,"eighty":-25.713912,"marketCap":2138726192},{"date":"2022-12-16","current":-18.028246,"twenty":-51.7604,"median":-40.772608,"eighty":-25.598799,"marketCap":2393357876},{"date":"2022-12-23","current":-17.994359,"twenty":-51.70784,"median":-40.745253,"eighty":-25.338499,"marketCap":2388859083},{"date":"2022-12-30","current":-18.001136,"twenty":-51.570726,"median":-40.701201,"eighty":-25.184081,"marketCap":2389758841},{"date":"2023-01-06","current":-16.049206,"twenty":-51.363479,"median":-40.623172,"eighty":-24.85486,"marketCap":2130628364},{"date":"2023-01-13","current":-18.78733,"twenty":-51.102161,"median":-40.574619,"eighty":-24.231092,"marketCap":2494130839},{"date":"2023-01-20","current":-18.882216,"twenty":-50.978262,"median":-40.523325,"eighty":-23.99114,"marketCap":2506727459},{"date":"2023-01-27","current":-19.925957,"twenty":-50.965686,"median":-40.469321,"eighty":-23.312385,"marketCap":2645290284},{"date":"2023-02-03","current":-21.220466,"twenty":-50.951221,"median":-40.311267,"eighty":-22.57339,"marketCap":2817144176},{"date":"2023-02-10","current":-19.627745,"twenty":-50.890949,"median":-40.250171,"eighty":-21.596594,"marketCap":2605700905},{"date":"2023-02-17","current":-20.664708,"twenty":-50.876484,"median":-40.190227,"eighty":-21.430411,"marketCap":2743363971},{"date":"2023-02-24","current":-19.485417,"twenty":-50.857197,"median":-40.120759,"eighty":-21.251213,"marketCap":2586805975},{"date":"2023-03-03","current":-20.834146,"twenty":-50.688437,"median":-40.045986,"eighty":-21.055509,"marketCap":2765857936},{"date":"2023-03-10","current":-18.204462,"twenty":-50.646894,"median":-39.953806,"eighty":-20.967665,"marketCap":2416751599},{"date":"2023-03-17","current":-22.814647,"twenty":-50.628165,"median":-39.81605,"eighty":-20.881589,"marketCap":2929925462},{"date":"2023-03-24","current":-22.508745,"twenty":-50.547877,"median":-39.758269,"eighty":-20.937818,"marketCap":2890640524},{"date":"2023-03-31","current":-24.884826,"twenty":-50.538628,"median":-39.648544,"eighty":-20.967665,"marketCap":3195783993},{"date":"2023-04-06","current":-22.608341,"twenty":-50.398102,"median":-39.410762,"eighty":-20.985573,"marketCap":2903430969},{"date":"2023-04-14","current":-23.753697,"twenty":-50.260054,"median":-39.321908,"eighty":-21.029355,"marketCap":3050521084},{"date":"2023-04-21","current":-24.273021,"twenty":-50.211876,"median":-39.198908,"eighty":-21.041663,"marketCap":3117214118},{"date":"2023-04-28","current":-22.053448,"twenty":-50.10983,"median":-39.086878,"eighty":-21.052864,"marketCap":2832169920},{"date":"2023-05-05","current":-20.085339,"twenty":-50.030853,"median":-39.045525,"eighty":-21.029355,"marketCap":2579419472},{"date":"2023-05-12","current":-21.254175,"twenty":-50.011348,"median":-38.97946,"eighty":-20.981096,"marketCap":2729524925},{"date":"2023-05-19","current":-21.074906,"twenty":-49.936988,"median":-38.858126,"eighty":-20.935287,"marketCap":2706502616},{"date":"2023-05-26","current":-18.98821,"twenty":-49.739821,"median":-38.781427,"eighty":-20.865452,"marketCap":2438522942},{"date":"2023-06-02","current":-23.7011,"twenty":-49.634889,"median":-38.748697,"eighty":-20.83367,"marketCap":2555476271},{"date":"2023-06-09","current":-19.16437,"twenty":-49.587066,"median":-38.685442,"eighty":-20.780404,"marketCap":2066321490},{"date":"2023-06-16","current":-19.591955,"twenty":-49.518553,"median":-38.668128,"eighty":-20.758997,"marketCap":2112424156},{"date":"2023-06-23","current":-18.642716,"twenty":-49.490829,"median":-38.652026,"eighty":-20.740419,"marketCap":2010076237},{"date":"2023-06-30","current":-18.830853,"twenty":-49.425691,"median":-38.650282,"eighty":-20.728887,"marketCap":2030361410},{"date":"2023-07-07","current":-18.753888,"twenty":-49.321753,"median":-38.534252,"eighty":-20.640309,"marketCap":2022062930},{"date":"2023-07-14","current":-21.12271,"twenty":-49.135663,"median":-38.486364,"eighty":-20.586625,"marketCap":2277471700},{"date":"2023-07-21","current":-20.626711,"twenty":-49.077653,"median":-38.375503,"eighty":-20.595005,"marketCap":2223992607},{"date":"2023-07-28","current":-21.105606,"twenty":-49.061015,"median":-38.330676,"eighty":-20.595005,"marketCap":2275627593},{"date":"2023-08-04","current":-20.883262,"twenty":-49.007339,"median":-38.158206,"eighty":-20.613914,"marketCap":2251654207},{"date":"2023-08-11","current":-20.549746,"twenty":-48.954208,"median":-37.988814,"eighty":-20.586625,"marketCap":2215694127},{"date":"2023-08-18","current":-20.01954,"twenty":-48.941266,"median":-37.845067,"eighty":-20.541194,"marketCap":2158526822},{"date":"2023-08-25","current":-20.66947,"twenty":-48.894876,"median":-37.770349,"eighty":-20.506987,"marketCap":2228602874},{"date":"2023-09-01","current":-25.511357,"twenty":-48.832826,"median":-37.755599,"eighty":-20.541194,"marketCap":2375209352},{"date":"2023-09-07","current":-24.043412,"twenty":-48.807682,"median":-37.686377,"eighty":-20.560008,"marketCap":2238537799},{"date":"2023-09-14","current":-23.412009,"twenty":-48.750972,"median":-37.671633,"eighty":-20.577111,"marketCap":2179751687},{"date":"2023-09-22","current":-22.590183,"twenty":-48.595885,"median":-37.578261,"eighty":-20.58462,"marketCap":2103236431},{"date":"2023-09-28","current":-22.048981,"twenty":-48.583225,"median":-37.547623,"eighty":-20.587293,"marketCap":2052848336},{"date":"2023-10-05","current":-21.978825,"twenty":-48.576545,"median":-37.531928,"eighty":-20.595005,"marketCap":2046316545},{"date":"2023-10-11","current":-21.497757,"twenty":-48.562801,"median":-37.500901,"eighty":-20.605423,"marketCap":2001527127},{"date":"2023-10-20","current":-20.345196,"twenty":-48.534663,"median":-37.448341,"eighty":-20.589221,"marketCap":1894219146},{"date":"2023-10-27","current":-19.894194,"twenty":-48.514606,"median":-37.410785,"eighty":-20.580532,"marketCap":1852229066},{"date":"2023-11-03","current":-20.485508,"twenty":-48.433814,"median":-37.299311,"eighty":-20.506205,"marketCap":1907282726},{"date":"2023-11-10","current":-20.746087,"twenty":-48.370598,"median":-37.219715,"eighty":-20.506987,"marketCap":1931543661},{"date":"2023-11-17","current":-21.217133,"twenty":-48.32991,"median":-37.120374,"eighty":-20.524091,"marketCap":1975399966},{"date":"2023-11-24","current":-21.858558,"twenty":-48.320008,"median":-37.057747,"eighty":-20.549746,"marketCap":2035119191},{"date":"2023-11-30","current":-22.048981,"twenty":-48.252059,"median":-36.968279,"eighty":-20.57027,"marketCap":2052848336},{"date":"2023-12-07","current":-26.625426,"twenty":-48.121131,"median":-36.925787,"eighty":-20.578821,"marketCap":2015198621},{"date":"2023-12-15","current":-28.276615,"twenty":-48.00719,"median":-36.911135,"eighty":-20.582242,"marketCap":2140172179},{"date":"2024-01-05","current":-26.103359,"twenty":-47.918569,"median":-36.904212,"eighty":-20.585288,"marketCap":1975684923},{"date":"2024-01-12","current":-31.117632,"twenty":-47.865829,"median":-36.842529,"eighty":-20.591149,"marketCap":2355200212},{"date":"2024-01-19","current":-31.627558,"twenty":-47.844972,"median":-36.829603,"eighty":-20.601178,"marketCap":2393794988},{"date":"2024-01-26","current":-29.053645,"twenty":-47.78321,"median":-36.766338,"eighty":-20.619869,"marketCap":2198983265},{"date":"2024-02-02","current":-29.32075,"twenty":-47.731847,"median":-36.504107,"eighty":-20.628421,"marketCap":2219199576},{"date":"2024-02-09","current":-29.393596,"twenty":-47.672575,"median":-36.388531,"eighty":-20.635263,"marketCap":2224713115},{"date":"2024-02-16","current":-29.733547,"twenty":-47.618326,"median":-36.095963,"eighty":-20.635379,"marketCap":2250442965},{"date":"2024-02-23","current":-28.10664,"twenty":-47.602066,"median":-35.89466,"eighty":-20.635842,"marketCap":2127307254},{"date":"2024-03-01","current":-29.332891,"twenty":-47.570415,"median":-35.678665,"eighty":-20.651153,"marketCap":2220118499},{"date":"2024-03-08","current":-29.55143,"twenty":-47.518149,"median":-35.35785,"eighty":-20.660918,"marketCap":2236659117},{"date":"2024-03-15","current":-26.009561,"twenty":-47.49129,"median":-35.24315,"eighty":-20.664708,"marketCap":2126463652},{"date":"2024-03-22","current":-25.786705,"twenty":-47.380514,"median":-34.925503,"eighty":-20.66947,"marketCap":2108243640},{"date":"2024-03-28","current":-24.935846,"twenty":-47.342533,"median":-34.589879,"eighty":-20.66947,"marketCap":2038679948},{"date":"2024-04-05","current":-25.071983,"twenty":-47.312176,"median":-34.414946,"eighty":-20.689994,"marketCap":2049810139},{"date":"2024-04-12","current":-25.888808,"twenty":-47.269427,"median":-33.423363,"eighty":-20.697474,"marketCap":2116591283},{"date":"2024-04-19","current":-23.631195,"twenty":-47.158961,"median":-33.184171,"eighty":-20.697474,"marketCap":1932015619},{"date":"2024-04-26","current":-22.916473,"twenty":-46.951231,"median":-33.003753,"eighty":-20.698257,"marketCap":1873582118},{"date":"2024-05-03","current":-23.897861,"twenty":-46.656905,"median":-32.649248,"eighty":-20.698257,"marketCap":1953817432},{"date":"2024-05-10","current":-23.114516,"twenty":-46.598159,"median":-32.247909,"eighty":-20.698257,"marketCap":1889773514},{"date":"2024-05-17","current":-24.517522,"twenty":-46.43348,"median":-31.759443,"eighty":-20.698257,"marketCap":2004479038},{"date":"2024-05-24","current":-22.904066,"twenty":-46.181838,"median":-31.451512,"eighty":-20.698257,"marketCap":1872567685},{"date":"2024-05-31","current":-20.986625,"twenty":-46.068748,"median":-31.128449,"eighty":-20.698257,"marketCap":1715803469},{"date":"2024-06-07","current":-20.224161,"twenty":-45.830813,"median":-30.643949,"eighty":-20.66395,"marketCap":1892880316},{"date":"2024-06-14","current":-21.429439,"twenty":-45.725202,"median":-30.31849,"eighty":-20.645029,"marketCap":2005688335},{"date":"2024-06-21","current":-21.357939,"twenty":-45.671397,"median":-29.967092,"eighty":-20.641966,"marketCap":1998996334},{"date":"2024-06-28","current":-23.247571,"twenty":-45.51108,"median":-29.932669,"eighty":-20.635726,"marketCap":2175856364},{"date":"2024-07-05","current":-22.542789,"twenty":-45.42729,"median":-29.794252,"eighty":-20.635726,"marketCap":2109892353},{"date":"2024-07-12","current":-21.439653,"twenty":-45.27192,"median":-29.668005,"eighty":-20.635726,"marketCap":2006644335},{"date":"2024-07-15","current":-21.807365,"twenty":-45.165128,"median":-29.6527,"eighty":-20.635726,"marketCap":2041060341},{"date":"2024-08-02","current":-20.438659,"twenty":-44.67116,"median":-29.473821,"eighty":-20.619869,"marketCap":1912956320},{"date":"2024-08-09","current":-18.937169,"twenty":-44.592228,"median":-29.326821,"eighty":-20.554877,"marketCap":1772424296},{"date":"2024-08-16","current":-19.846234,"twenty":-44.342086,"median":-29.065787,"eighty":-20.488395,"marketCap":1857508310},{"date":"2024-08-23","current":-19.366166,"twenty":-44.293477,"median":-28.968658,"eighty":-20.439367,"marketCap":1812576303},{"date":"2024-08-30","current":-20.193518,"twenty":-44.126836,"median":-28.878841,"eighty":-20.396729,"marketCap":1890012316},{"date":"2024-09-06","current":-20.851386,"twenty":-44.070828,"median":-28.815003,"eighty":-20.350301,"marketCap":1731811836},{"date":"2024-09-13","current":-19.495653,"twenty":-43.902513,"median":-28.750118,"eighty":-20.261779,"marketCap":1619211496},{"date":"2024-09-20","current":-20.358392,"twenty":-43.724824,"median":-28.493474,"eighty":-20.244564,"marketCap":1690866258},{"date":"2024-09-27","current":-20.324779,"twenty":-43.52784,"median":-28.425739,"eighty":-20.226358,"marketCap":1688074514},{"date":"2024-10-04","current":-19.753355,"twenty":-43.367535,"median":-28.373476,"eighty":-20.209123,"marketCap":1640614867},{"date":"2024-10-11","current":-20.30237,"twenty":-43.311657,"median":-28.264591,"eighty":-20.195561,"marketCap":1686213351},{"date":"2024-10-18","current":-21.030656,"twenty":-43.248031,"median":-28.136018,"eighty":-20.195561,"marketCap":1746701137},{"date":"2024-10-25","current":-20.078282,"twenty":-43.248031,"median":-28.049113,"eighty":-20.145499,"marketCap":1667601725},{"date":"2024-10-31","current":-20.649706,"twenty":-43.248031,"median":-27.765641,"eighty":-20.132647,"marketCap":1715061372},{"date":"2024-11-08","current":-22.688907,"twenty":-43.252213,"median":-27.636067,"eighty":-20.132233,"marketCap":1884427173},{"date":"2024-11-15","current":-21.960621,"twenty":-43.252213,"median":-27.448241,"eighty":-20.132233,"marketCap":1823939387},{"date":"2024-11-22","current":-22.229527,"twenty":-43.231304,"median":-27.106738,"eighty":-20.132233,"marketCap":1846273338},{"date":"2024-11-29","current":-25.707412,"twenty":-43.145724,"median":-26.876224,"eighty":-20.132233,"marketCap":1914893729},{"date":"2024-12-06","current":-25.40483,"twenty":-43.145724,"median":-26.625426,"eighty":-20.132233,"marketCap":1892354961},{"date":"2024-12-13","current":-24.521289,"twenty":-43.145724,"median":-26.466422,"eighty":-20.132233,"marketCap":1826541758},{"date":"2024-12-20","current":-22.572657,"twenty":-43.145724,"median":-26.327469,"eighty":-20.132233,"marketCap":1681392092},{"date":"2024-12-27","current":-22.173248,"twenty":-43.145724,"median":-26.203648,"eighty":-20.132233,"marketCap":1651640919},{"date":"2025-01-03","current":-21.785943,"twenty":-43.145724,"median":-26.12294,"eighty":-20.132233,"marketCap":1622791296},{"date":"2025-01-10","current":-21.434947,"twenty":-43.151859,"median":-25.994723,"eighty":-20.130744,"marketCap":1596646325},{"date":"2025-01-17","current":-22.584761,"twenty":-43.151859,"median":-25.832017,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-24","current":-22.584761,"twenty":-43.151859,"median":-25.722549,"eighty":-20.130744,"marketCap":1682293643},{"date":"2025-01-31","current":-22.330591,"twenty":-43.151859,"median":-25.688138,"eighty":-20.130744,"marketCap":1663361078},{"date":"2025-02-07","current":-23.032583,"twenty":-43.151859,"median":-25.544418,"eighty":-20.130744,"marketCap":1715651020},{"date":"2025-02-14","current":-23.601438,"twenty":-43.151859,"median":-25.410136,"eighty":-20.130744,"marketCap":1758023904},{"date":"2025-02-21","current":-22.149042,"twenty":-43.151859,"median":-25.353801,"eighty":-20.130744,"marketCap":1649837817},{"date":"2025-02-28","current":-21.229191,"twenty":-43.151859,"median":-25.248903,"eighty":-20.130744,"marketCap":1581319962},{"date":"2025-03-07","current":-20.902402,"twenty":-43.157994,"median":-25.114351,"eighty":-20.129255,"marketCap":1556978093},{"date":"2025-03-14","current":-25.841364,"twenty":-43.157994,"median":-25.015259,"eighty":-20.118618,"marketCap":1407320673},{"date":"2025-03-21","current":-31.526661,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1716941957},{"date":"2025-03-28","current":-31.810986,"twenty":-43.157994,"median":-25.094673,"eighty":-20.118618,"marketCap":1732426315},{"date":"2025-04-04","current":-28.415807,"twenty":-43.157994,"median":-25.140052,"eighty":-20.118618,"marketCap":1547524873},{"date":"2025-04-11","current":-25.672904,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1398146368},{"date":"2025-04-17","current":-25.238054,"twenty":-43.151859,"median":-25.115856,"eighty":-20.120859,"marketCap":1374464410},{"date":"2025-04-25","current":-26.22483,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1428204238},{"date":"2025-05-02","current":-26.007405,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1416363259},{"date":"2025-05-09","current":-26.208105,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1427293394},{"date":"2025-05-16","current":-28.064582,"twenty":-43.157994,"median":-25.054079,"eighty":-20.118618,"marketCap":1528397138},{"date":"2025-05-23","current":-26.826931,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1460994642},{"date":"2025-05-30","current":-40.212905,"twenty":-43.110374,"median":-25.054079,"eighty":-20.118618,"marketCap":1483896395},{"date":"2025-06-06","current":-38.417271,"twenty":-42.89345,"median":-25.054079,"eighty":-20.118618,"marketCap":1417635735},{"date":"2025-06-13","current":-37.443101,"twenty":-42.85482,"median":-25.054079,"eighty":-20.118618,"marketCap":1381687885},{"date":"2025-06-20","current":-35.644634,"twenty":-42.692819,"median":-25.045717,"eighty":-20.116377,"marketCap":1315322623},{"date":"2025-06-27","current":-37.218293,"twenty":-42.4845,"median":-25.045717,"eighty":-20.116377,"marketCap":1373392227},{"date":"2025-07-03","current":-39.940973,"twenty":-42.385562,"median":-25.045717,"eighty":-20.116377,"marketCap":1473861860},{"date":"2025-07-11","current":-39.516335,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1458192284},{"date":"2025-07-18","current":-36.593825,"twenty":-42.275719,"median":-25.045717,"eighty":-20.116377,"marketCap":1350348733}],"updateTime":1753158113937}}}